IP Library Granted Patent US 7,279,327
Granted Patent B2
US 7,279,327 · App. 10/474,962 · Granted Oct 9, 2007

Methods for producing recombinant coronavirus

Assignee: The University of North Carolina at Chapel Hill
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,279,327
App. No.
10/474,962
Granted
Oct 9, 2007
Kind
B2
Abstract

A helper cell for producing an infectious, replication defective, coronavirus (or more generally nidovirus) particle cell comprises (a) a nidovirus permissive cell; (b) a nidovirus replicon RNA comprising the nidovirus packaging signal and a heterologous RNA sequence, wherein the replicon RNA further lacks a sequence encoding at least one nidovirus structural protein; and (c) at least one separate helper RNA encoding the at least one structural protein absent from the replicon RNA, the helper RNA(s) lacking the nidovirus packaging signal. The combined expression of the replicon RNA and the helper RNA in the nidovirus permissive cell produces an assembled nidovirus particle which comprises the heterologous RNA sequence, is able to infect a cell, and is unable to complete viral replication in the absence of the helper RNA due to the absence of the structural protein coding sequence in the packaged replicon. Compositions for use in making such helper cells, along with viral particles produced from such cells, compositions of such viral particles, and methods of making and using such viral particles, are also disclosed.

Claims (20)

1. A helper cell for producing an infectious, replication defective, coronavirus particle, wherein said cell is a coronavirus permissive cell, comprising:

(a) a coronavirus replicon RNA comprising a coronavirus packaging signal, and a heterologous RNA sequence, wherein said replicon RNA further lacks a sequence encoding at least one coronavirus structural protein; and

(b) at least one separate helper RNA encoding the at least one structural protein absent from the replicon RNA, said helper RNA lacking a coronavirus packaging signal.

wherein the combined expression of the replicon RNA and the helper RNA produces an assembled coronavirus particle which comprises said heterologous RNA sequence, is able to infect a cell, and is replication defective.

2. The helper cell according to claim 1 , said replicon RNA further comprising a sequence encoding at least one of the coronavinis structural proteins.

3. The helper cell according to claim 1 , wherein said helper RNA contains at least one gene encoding a structural protein selected from the group consisting of the E, M, N, and S genes.

4. The helper cell according to claim 1 , wherein said helper RNA contains the E gene.

5. The helper cell according to claim 1 , wherein said coronavirus is selected from the group consisting of human respiratory coronavirus, mouse hepatitis virus, porcine transmissible gastroenteritis virus, porcine respiratory coronavirus, canine coronavirus, feline enteric coronavirus, feline infectious peritonitis virus, rabbit coronavirus, murine hepatitis virus, sialodacryoadenitis virus, porcine hemagglutinating encephaloinyclitis virus, bovine coronavirus, avian infectious bronchitis virus, and flu-key coronavirus.

6. The helper cell according to claim 1 , wherein said coronavirus is transmissible gastroenteritis virus.

7. The helper cell according to claim 1 , wherein said replicon RNA contains at least one attenuating gene order rearrangement among the 3A, 3B, HP, S, E, M and N genes.

8. The helper cell according to claim 1 , wherein said helper RNA includes a promoter.

9. The helper cell according to claim 1 , wherein said replicon RNA includes a promoter.

10. The helper cell according to claim 1 , wherein said heterologous RNA is selected from the group consisting of RNA encoding proteins and RNA encoding peptides.

11. The helper cell according to claim 1 , further comprising a heterologous DNA encoding said helper RNA.

12. The helper cell according to claim 1 , further comprising a heterologous DNA encoding said replicon RNA.

13. A method of making infectious, replication defective, coronavirus particles, comprising:

providing a helper cell according to claim 1 ;

producing said coronavirus particles in said helper cell; and then

collecting said coronavirus particles from said helper cell.

14. The method according to claim 13 , wherein said coronavinis RNA and said at least one separate helper RNA are introduced into said helper cell by electroporation.

Assignments (2)
CONFIRMATORY LICENSE Recorded Dec 17, 2018
From: UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 047928/0033 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 27, 2004
From: CURTIS, KRISTOPHER M.; YOUNT, BOYD; BARIC, RALPH S.
To: NORTH CAROLINA AT CHAPEL HILL, THE UNIVERSITY OF
Reel/Frame 015378/0157 →
Continuity (3)
Provisional Application 6028532000 · Apr 20, 2001
Provisional Application 6028531800 · Apr 20, 2001
Related Publication 20040235132A1 · Nov 25, 2004